CervoMed’s (CRVO) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CervoMed (NASDAQ:CRVO) in a report published on Monday morning,Benzinga reports. They currently have a $31.00 target price on the stock.

A number of other research firms also recently weighed in on CRVO. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, January 21st. Brookline Capital Acquisition raised CervoMed to a “strong-buy” rating in a report on Tuesday, February 3rd. Cantor Fitzgerald assumed coverage on shares of CervoMed in a research note on Thursday, December 18th. They issued an “overweight” rating for the company. Chardan Capital restated a “buy” rating and set a $15.00 target price on shares of CervoMed in a report on Thursday, March 5th. Finally, Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

CervoMed Price Performance

CervoMed stock opened at $4.24 on Monday. The firm has a 50-day moving average of $5.28 and a 200-day moving average of $7.21. CervoMed has a one year low of $3.58 and a one year high of $16.94. The company has a market cap of $39.26 million, a price-to-earnings ratio of -1.42 and a beta of -0.77.

CervoMed (NASDAQ:CRVO) last released its earnings results on Friday, March 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.09). CervoMed had a negative net margin of 672.80% and a negative return on equity of 96.04%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.84 million. As a group, sell-side analysts expect that CervoMed will post -1.88 earnings per share for the current year.

Institutional Trading of CervoMed

Several institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. increased its holdings in shares of CervoMed by 8,425,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock worth $666,000 after acquiring an additional 84,259 shares during the last quarter. Jane Street Group LLC acquired a new stake in CervoMed during the 2nd quarter valued at $414,000. Citadel Advisors LLC acquired a new stake in CervoMed during the 3rd quarter valued at $247,000. Savvy Advisors Inc. bought a new position in CervoMed during the third quarter worth $210,000. Finally, AQR Capital Management LLC bought a new position in CervoMed during the first quarter worth $227,000. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.